Incidence of hepatitis B viraemia, detected using the polymerase chain reaction, after successful therapy of hepatitis B virus carriers with interferon–α

Publisher Website
Google Scholar
Abstract
Thirty‐nine patients (62 sera) who, after interferon‐α therapy for chronic hepatitis B virus (HBV) infection, were seronegative for HBeAg and HBV‐DNA by dot blot hybridisation, were tested using the polymerase chain reaction (PCR) for residual viraemia. Overall, 59% of the HBsAg‐positive sera and 43% of the HBsAg‐negative sera were positive by PCR. All except one of the HBsAg‐negative patients had seroconverted to anti‐HBs. Between 13 and 18 months after therapy, 33% of the HBsAg‐positive and 20% of the HBsAg‐negative patients remained viraemic. Eighteen months after the end of treatment, no patient tested was positive. Twenty‐three patients were tested sequentially over periods from 1 to 43 months: Thirteen lost HBV‐DNA by PCR, three remained positive, five remained negative, and two patients relapsed. The merits and disadvantages of PCR for assessing interferon treatment of HBV carriers are discussed.

This publication has 11 references indexed in Scilit: